Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Biotech IPO activity remains strong in 2026
- With three companies filing to go public this week, the biotech initial public offering market remains strong. The companies are looking to fund development programs in cardiovascular, immunology and cardiometabolic, adding to a year that has already seen at least 18 biotech IPOs—more than double 2025’s.
- According to BioSpace, the companies plan to use IPO proceeds to advance key clinical programs, including funding a Phase 3 development of a hypertrophic cardiomyopathy drug, advancing multiple immunology candidates and supporting mid-stage studies in metabolic disease.
FDA releases new complete response letters after three-month pause
- The U.S. Food and Drug Administration released 14 new complete response letters (CRLs), which are formal drug application rejection letters, after a roughly three‑month pause in its transparency initiative. The newly published letters span rejections from April through July 2026.
- The publication program was suspended in April after a pharmaceutical company challenged the policy, arguing for greater sponsor involvement and protection of confidential information. Despite the pause, the FDA continues to pursue broader transparency measures, including a proposed rule and prior legislative requests that would strengthen its authority to publicly release CRLs, according to Fierce Biotech.
UK life sciences attracts major investment over past 12 months
- According to a press release from gov.uk, the UK life sciences industry has attracted more than £3 billion in new public-private investment over the past 12 months, driven by major commitments from significant UK-based businesses.
- The UK government’s Life Sciences Sector Plan has cut clinical trial setup time from 169 to 122 days and allowed patients to access new medicines up to six months sooner. In addition, under the plan a dedicated new jobs plan will target 66,000 additional sector roles by 2035.
New healthcare reform bill in Germany could drive out drugmakers
- Germany’s parliament approved a healthcare reform bill aimed at saving the country’s public health insurance system about €16.3 billion in 2027, including increasing mandatory discounts that drugmakers must provide on patented medicines. The pharmaceutical industry strongly opposes the measure, arguing it could discourage investment and drive companies out of Germany, reports Endpoints News.
- The bill comes amid broader scrutiny of Germany’s drug-pricing system, including a U.S. trade investigation. Industry groups warn the impact could extend beyond Germany because its drug prices are often used as benchmarks across Europe and could influence international drug-pricing policies.
AI-powered drug discovery partnership launched
- An artificial intelligence drug discovery company and a contract development and manufacturing organization (CDMO) formed a multi-target drug discovery partnership worth up to $2.5 billion. The partnership, which combines the company’s AI-powered platform with the CDMO’s development, manufacturing and commercialization capabilities, will accelerate the creation of new medicines.
- According to Fierce Pharma, the deal highlights growing industry adoption of AI in drug development. The AI drug discovery company says its platform can generate pre-clinical candidates in 12 to 18 months versus the industry’s typical 2.5 to 4 years. The partnership is expected to help the CDMO expand AI capabilities across its operations while supporting a more integrated path of drug discovery through commercialization.
For more insights in life sciences, check out RSM’s industry outlook.
